<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2020v4.1">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2021-11-15T18:50:10-06:00</ReturnTs>
    <TaxPeriodEndDt>2020-12-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>271728945</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>PKF O'CONNOR DAVIES LLP</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>500 MAMARONECK AVENUE</AddressLine1Txt>
        <CityNm>HARRISON</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>105281633</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2020-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>133859563</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>THE ZACHARY &amp; ELIZABETH M FISHER CENTER</BusinessNameLine1Txt>
        <BusinessNameLine2Txt>FOR ALZHEIMER'S RESEARCH FOUNDATION</BusinessNameLine2Txt>
      </BusinessName>
      <BusinessNameControlTxt>ZACH</BusinessNameControlTxt>
      <PhoneNum>2129151328</PhoneNum>
      <USAddress>
        <AddressLine1Txt>FDR STATION PO BOX 220</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10150</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>BARRY R SLOANE</PersonNm>
      <PersonTitleTxt>CHAIRMAN &amp; TREASURER</PersonTitleTxt>
      <PhoneNum>2129151328</PhoneNum>
      <SignatureDt>2021-11-15</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <SigningOfficerGrp>
      <PersonFullName>
        <PersonFirstNm>BARRY</PersonFirstNm>
        <PersonLastNm>SLOANE</PersonLastNm>
      </PersonFullName>
      <SSN>999009999</SSN>
    </SigningOfficerGrp>
    <PreparerPersonGrp>
      <PreparerPersonNm>GARRETT M HIGGINS</PreparerPersonNm>
      <PTIN>P00543209</PTIN>
      <PhoneNum>9143818900</PhoneNum>
      <PreparationDt>2021-11-15</PreparationDt>
    </PreparerPersonGrp>
    <AdditionalFilerInformation>
      <TrustedCustomerGrp>
        <TrustedCustomerCd>2</TrustedCustomerCd>
        <AuthenticationAssuranceLevelCd>AAL1</AuthenticationAssuranceLevelCd>
        <IdentityAssuranceLevelCd>IAL1</IdentityAssuranceLevelCd>
      </TrustedCustomerGrp>
    </AdditionalFilerInformation>
    <TaxYr>2020</TaxYr>
    <BuildTS>2022-09-23 18:48:47Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="10">
    <IRS990 documentId="RetDoc1038000001" referenceDocumentId="RetDoc1044400001">
      <DoingBusinessAsName>
        <BusinessNameLine1Txt>ALZHEIMER'S RESEARCH FOUNDATIONFISHER CENTER</BusinessNameLine1Txt>
      </DoingBusinessAsName>
      <PrincipalOfficerNm>BARRY R SLOANE</PrincipalOfficerNm>
      <USAddress>
        <AddressLine1Txt>FDR STATION PO BOX 220</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10150</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>13602731</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>0</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>WWW.ALZINFO.ORG</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>1995</FormationYr>
      <LegalDomicileStateCd>NY</LegalDomicileStateCd>
      <ActivityOrMissionDesc>THE FOUNDATION FUNDS RESEARCH INTO THE CAUSE, CARE, AND CURE OF ALZHEIMER'S DISEASE AT THE ZACHARY AND ELIZABETH M. FISHER CENTER FOR RESEARCH ON ALZHEIMER'S DISEASE AT THE ROCKEFELLER UNIVERSITY IN NEW YORK THAT WAS UNDER THE DIRECTION OF NOBEL LAUREATE DR. PAUL GREENGARD WHOSE FINDINGS HAVE BEEN THE BASIS FOR MUCH OF TODAY'S ALZHEIMER'S INVESTIGATIONS.</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>12</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>11</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>4</TotalEmployeeCnt>
      <TotalVolunteersCnt>13</TotalVolunteersCnt>
      <TotalGrossUBIAmt>0</TotalGrossUBIAmt>
      <NetUnrelatedBusTxblIncmAmt>0</NetUnrelatedBusTxblIncmAmt>
      <PYContributionsGrantsAmt>6868429</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>7458789</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>0</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>0</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>2253116</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>2536517</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>3000</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>385</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>9124545</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>9995691</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>3430534</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>4959013</CYGrantsAndSimilarPaidAmt>
      <PYBenefitsPaidToMembersAmt>0</PYBenefitsPaidToMembersAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>742488</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>587743</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>0</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>0</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>384270</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>501354</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>1030154</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>4674376</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>6576910</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>4450169</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>3418781</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>31521960</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>34799750</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>2890733</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>2445530</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>28631227</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>32354220</NetAssetsOrFundBalancesEOYAmt>
      <InfoInScheduleOPartIIIInd>X</InfoInScheduleOPartIIIInd>
      <MissionDesc>THE ZACHARY AND ELIZABETH M. FISHER CENTER FOR ALZHEIMER'S RESEARCH FOUNDATION IS DEDICATED TO ATTACKING THE SCOURGE OF ALZHEIMER'S DISEASE THROUGH A 3-PRONGED ASSAULT FOCUSED ON UNDERSTANDING THE CAUSE OF ALZHEIMER'S DISEASE (AD), IMPROVING THE CARE OF PEOPLE LIVING WITH THE DISEASE TO ENHANCE THEIR QUALITY OF LIFE AND THAT OF THEIR CAREGIVERS AND FAMILIES, AND FINDING A CURE.</MissionDesc>
      <SignificantNewProgramSrvcInd>0</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>0</SignificantChangeInd>
      <ExpenseAmt>4059013</ExpenseAmt>
      <GrantAmt>4059013</GrantAmt>
      <Desc>A MAJORITY OF OUR GRANT FUNDING GOES TO THE ZACHARY AND ELIZABETH M. FISHER CENTER FOR RESEARCH ON ALZHEIMER'S DISEASE (THE FISHER CENTER LAB) AT THE ROCKEFELLER UNIVERSITY IN NEW YORK FOR NEUROLOGICAL RESEARCH INTO THE CAUSE OF ALZHEIMER'S AND POTENTIAL NEW PHARMACOLOGICAL TREATMENT OPTIONS. THE LAB IS UNDER THE INTERIM DIRECTION OF DR. MARC FLAJOLET SINCE THE PASSING OF NOBEL LAUREATE DR. PAUL GREENGARD IN 2019. THE FISHER CENTER PROVIDES RESEARCHERS WORLDWIDE WITH A CONCEPTUAL FRAMEWORK FOR UNDERSTANDING THE DISEASE PROCESS, AND CONTINUES TO BE AT THE FOREFRONT OF ONE DAY FINDING A CURE FOR ALZHEIMER'S DISEASE. DURING THE CALENDAR YEAR RESEARCHERS DISCOVERED THAT SPECIFIC TYPES OF NERVE CELLS (NEURONS) ARE MORE SUSCEPTIBLE TO THE ALZHEIME'S DISEASE PATHOLOGY, BEING AFFECTED AND DISAPPEARING SOONER THAN OTHER NEURONS (RESISTANT). FISHER SCIENTISTS ARE USING A UNIQUE SET OF TECHNOLOGIES TO BETTER UNDERSTAND UNDERLYING CAUSES OF THIS PROCESS AND HELP DESIGN ENTIRELY NEW THERAPEUTIC STRATEGIES. NEW GENES ARE BEING CHARACTERIZED THAT THEY HAVE LINKED TO VULNERABILITY. A SECOND RELATIVELY NEW PROJECT IS CENTERED ON OUR DISCOVERY THAT A DIFFERENT FRAGMENT OF APP (CALLED C99) IS A BETTER MARKER FOR NEURODEGENERATION. THIS STUDY WAS MOSTLY BASED ON HUMAN BRAIN SAMPLES WHICH GIVES IT EVEN MORE VALUE. IN OTHER RESEARCH, THE SCIENTISTS ACCELERATED THE BREAKDOWN OF THE TOXIC BETA-AMYLOID COMPONENT BY TARGETING A CELLULAR PROCESS CALLED AUTOPHAGY, A PROCESS RESPONSIBLE FOR REMOVING DEBRIS FROM THE CELLS. THE SCIENTISTS IDENTIFIED A NOVEL SIGNALING NETWORK WITHIN NEURONS THAT REGULATES BETA-AMYLOID DEGRADATION. SCIENTISTS CONTINUE TO DEVELOP THERAPEUTIC APPROACHES AND BUILD A NOVEL PLATFORM FOR DRUG DISCOVERY APPLICATIONS AS THEY CHARACTERIZE AND OPTIMIZE CHEMICALLY ACTIVE MOLECULES. ONE MOLECULE IDENTIFIED MIGHT HELP PROTECT PEOPLE FROM DEVELOPING ALZHEIMER'S DISEASE.</Desc>
      <ProgSrvcAccomActy2Grp>
        <ExpenseAmt>785304</ExpenseAmt>
        <Desc>THE ALZHEIMER'S INFORMATION PROGRAM PROMOTES PUBLIC DISEASE AWARENESS, EDUCATION, AND RESOURCES FOR CAREGIVERS (AND PATIENTS) THROUGH MEDIA CONDUITS, SOCIAL NETWORKS, AND THE INTERNET. THE HEART OF THE PROGRAM IS THE WEBSITE, ALZINFO.ORG, WHICH IS UPDATED REGULARLY TO PROVIDE COMPREHENSIVE DATA ABOUT ALZHEIMER'S DISEASE, RECENT RESEARCH STUDIES AND FINDINGS, TREATMENT AND DISEASE MANAGEMENT. THE SITE HAD 433,760 UNIQUE VISITORS AND OFFERS A FREE RESOURCE LOCATOR THAT IDENTIFIES DOCTORS, NURSES, GERIATRIC CAREGIVERS, HOME HEALTH AGENCIES AND OTHER SOURCES BY ZIP CODE. OUR SCIENTISTS ANSWER QUESTIONS THROUGH "ASK THE EXPERTS" PORTAL ON OUR WEBSITE, AND CAREGIVERS CAN JOIN OUR SUPPORT GROUP THROUGH OUR ONLINE CAREGIVER'S CORNER. OUR 1-800-ALZ-INFO PHONE SYSTEM ASSISTS PEOPLE WHO DO NOT HAVE ACCESS TO THE INTERNET. OUR SCIENTISTS ANSWER QUESTIONS THROUGH THE "ASK THE EXPERTS" FEATURE ON OUR WEBSITE; OUR FREE E-NEWSLETTER, ALZHEIMER'S RESEARCH NEWS YOU CAN USE, IS THE MOST REVIEWED ALZHEIMER'S AND DEMENTIA NEWSLETTER ON THE INTERNET; AND CAREGIVERS CAN JOIN OUR SUPPORT GROUP THROUGH OUR ONLINE CAREGIVER'S CORNER. OUR 1-800-ALZ-INFO PHONE SYSTEM ASSISTS PEOPLE WHO DO NOT HAVE ACCESS TO THE INTERNET. OUR AWARD-WINNING TRI-ANNUAL PRINT PUBLICATION (PRESERVING YOUR MEMORY) CIRCULATES 51,500 COPIES PER ISSUE, WITH AN ESTIMATED READERSHIP OF 772,500. THE EDITORIAL CONTENT IS REVIEWED BY OUR SCIENTIFIC TEAM FOR ACCURACY AND VALIDITY AS IT ADDRESSES CONCERNS OF READERS AFFECTED BY THE DISEASE (WHETHER CAREGIVER OR PATIENT), AND PROVIDES INFORMATION ABOUT ALZHEIMER'S TREATMENT, CARE OPTIONS, AND HOW TO TAKE THE NECESSARY STEPS TO ADEQUATELY PREPARE IF THEY, OR SOMEONE THEY LOVE, RECEIVE(S) AN ALZHEIMER'S DIAGNOSIS.</Desc>
      </ProgSrvcAccomActy2Grp>
      <ProgSrvcAccomActy3Grp>
        <ExpenseAmt>750000</ExpenseAmt>
        <GrantAmt>750000</GrantAmt>
        <Desc>DURING THE PANDEMIC, THE FISHER CENTER LAB AT THE ROCKEFELLER UNIVERSITY CAMPUS WAS PART OF AN ORGANIZED COLLECTION OF MEDICAL ITEMS INCLUDING BOXES OF GLOVES, MASKS, HARD FACE SHIELDS AND LAB GOGGLES TO PROVIDE TO HOSPITALS IN NEED. IN ADDITION, ONE LARGE EFFORT THAT THE FISHER CENTER LAB SCIENTISTS TOOK OVER THE LAST YEAR AND A HALF WAS TO BUILD A TOTALLY NOVEL DRUG DISCOVERY PLATFORM THAT WILL CONSIDERABLY SPEED UP THE DRUG DISCOVERY PROCESS FOR ALZHEIMER'S DISEASE. DUE TO THE URGENT NEEDS FOR NEW DRUGS FOR THE CORONAVIRUS, DR. FLAJOLET AND THE ROCKEFELLER UNIVERSITY LEADERS IMMEDIATELY IDENTIFIED THAT SOME OF THE SCIENTIFIC KNOWLEDGE AT THE FISHER CENTER LAB COULD BE USED TO HELP WITH COVID-19 EFFORTS. OUR TEAM OF SCIENTISTS DILIGENTLY WORKED LONG HOURS, SEVEN DAYS A WEEK, IN MARCH AND APRIL TO BRING THE SCREENING PLATFORM TO A FUNCTIONAL LEVEL, AND IT IS NOW READY FOR DRUG DISCOVERY. ADDITIONALLY, THE FISHER CENTER LAB TEAM WORKED ON TWO PROTEINS OF COVID-19 THAT BELONG TO A FAMILY OF PROTEINS THAT THEY UNDERSTAND VERY WELL. THEY WILL ALSO MAKE THEIR DRUG DISCOVERY PLATFORM AVAILABLE TO OTHER SCIENTISTS WORKING ON OTHER PROTEIN TARGETS OF COVID-19.</Desc>
      </ProgSrvcAccomActy3Grp>
      <ProgSrvcAccomActyOtherGrp>
        <ExpenseAmt>150000</ExpenseAmt>
        <GrantAmt>150000</GrantAmt>
        <Desc>A GRANT WAS GIVEN TO THE BRAIN AND SPINE IMAGING INSTITUTE TO CARRY OUT RESEARCH BY BENOIT DELATOUR, MARC DHENAIN, PATRICE DUBREUIL, AND OLIVIER HERMINE TO INVESTIGATE WHETHER STRUCTURE OF AMYLOID PROTEINS ARE CHANGED PARTICULARLY IF PROTEINS AGGREGATES, WHICH ARE TOXIC FOR SYNAPSES, ARE DECREASED. IN THIS HYPOTHESIS, MASITINIB MAY DECREASE PROTEASE RELEASE BY MAST CELLS, WHICH MAY BE RESPONSIBLE FOR GENERATION OF PROTEINS AGGREGATE, AND TEST WHETHER MASITINIB IS ABLE TO BLOCK LESIONS SPREADING AFTER PRIONS LIKE PROTEINS INOCULATION. THIS PROJECT WILL REVEAL ROLE OF MAST CELL AND KINASES IN THE PATHOPHYSIOLOGY OF ALZHEIMER DISEASE. A BETTER UNDERSTANDING OF ITS MECHANISMS MAY DEFINE THE BEST STRATEGY TO IMPROVE ALZHEIMER'S DISEASE. THE TEAM REPORTED THAT MASITINIB IS A DRUG-LIKE COMPOUND WHICH INHIBITS A TYPE OF SIGNALING PROTEIN CALLED A KINASE. KINASES ARE IMPORTANT REGULATORS OF CELLULAR COMMUNICATION. INITIALLY, MASITINIB HAS BEEN SHOWN TO SPECIFICALLY BLOCK THE ACTIVITY OF THREE SUCH KINASES: C-KIT, LYN AND FYN. THESE ARE IMPORTANT FOR A TYPE OF CELLS CALLED MAST CELLS. SIGNALING OF MAST CELLS PLAY A CRUCIAL ROLE FOR THE IMMUNE SYSTEM AND THE BRAIN. MASITINIB HAS ALSO BEEN SHOWN TO TARGET ANOTHER KINASE CALLED MCSFR-1 THAT PLAYS A CRITICAL ROLE IN MICROGLIA MODULATION. MICROGLIA IS A TYPE OF CELL THAT HAS A SCAVENGER FUNCTION IN THE BRAIN AND IS BELIEVED TO BE HIGHLY RELEVANT FOR AD. IN SUMMARY, MASITINIB COULD ACT ON FOUR DIFFERENT TARGETS THAT INVOLVE DYSFUNCTIONAL MECHANISMS IN AD: MODULATION OF MICROGLIA, PROTECTION OF SYNAPSES, INHIBITION OF TAU PROTEIN, AND CONTROL OF MAST CELL ACTIVITY. IN ONE EXPERIMENT (THE MORRIS WATER MAZE TEST), A MOUSE MODEL OF ALZHEIMER'S DISEASE WAS USED AND COMPARED TO NORMAL MICE. THE TEST MEASURED THE ABILITY OF MICE TO MEMORIZE THE LOCATION OF A SMALL SUBMERGED PLATFORM IN A POOL OF MILKY WATER. AFTER SEVERAL ATTEMPTS, NORMAL MICE MEMORIZE THE LOCATION OF THE PLATFORM, LOCATING THE SUBMERGED PLATFORM QUICKLY, WHILE AD MICE WERE SIGNIFICANTLY SLOWER. MASITINIB SIGNIFICANTLY IMPROVED THE COGNITIVE ABILITY IN AD MICE IN THIS TEST. SIMILARLY, MASITINIB COULD PROTECT AGAINST SYNAPTIC LOSS (THE ACTIVE ZONES BETWEEN NEURONS WHICH ARE CRUCIAL FOR NEURONAL COMMUNICATION) BY REDUCING MAST CELL ACTIVITY. IN A NOVEL CLINICAL TRIAL, THREE VARYING DOSES OF MASITINIB WERE TESTED ON AD PATIENTS: 3 MG/KG/DAY, 4.5 MG/KG/DAY AND TITRATION FROM 4.5 TO 6 MG/KG/DAY. EARLY ON, THE STUDY ARM INVOLVING THE LOWER DOSE WAS STOPPED. THE STUDY ENROLLED 718 PATIENTS FROM 118 SITES IN 21 COUNTRIES. THE LATEST RESULTS REPORTED CORRESPOND TO 24 WEEKS OF TREATMENT. SIGNIFICANT EFFECTS WERE OBSERVED IN THE AREAS OF COGNITIVE FUNCTION, DAILY ACTIVITY, AND 71% IMPROVEMENT ON CIBIC, AS WELL AS SOME NUMERICAL ADVANTAGES (NOT STATISTICALLY SIGNIFICANT) OF MASITINIB ON OTHER TESTS (MMSE, CDR AND NPI). FROM THOSE ENCOURAGING STUDIES, IT IS POSSIBLE TO CONCLUDE THAT 4.5 MG/KG/DAY REPRESENTS THE EFFECTIVE DOSE FOR AD.A GRANT WAS MADE TO THE NEW YORK UNIVERSITY SCHOOL OF MEDICINE FOR THE FISHER ALZHEIMER'S DISEASE EDUCATION AND RESOURCES PROGRAM WHERE DRS. REISBERG AND KENOWSKY EXAMINED HEALTH OUTCOMES OF THE COMPREHENSIVE,INDIVIDUALIZED, PATIENT CENTERED ALZHEIMER'S MANAGEMENT PROGRAM.PRIMARY RESEARCH FOCUSED ON THE EFFECTS OF THE PROGRAM ON ANTIDEPRESSANT USAGE AND COST. PREVIOUSLY THEY DESCRIBED THE STAGES OF ALZHEIMER'S DISEASE (AD) THAT IMPROVED WORLDWIDE UNDERSTANDING OF AD AND ASSISTED IN THE DISCOVERY OF NEW TREATMENTS FOR AD. FOR EXAMPLE, A STAGE OF "MILD COGNITIVE IMPAIRMENT," (MCI) PRIOR TO THE ADVENT OF THE DEMENTIA OF AD AND A STAGE OF "SUBJECTIVE COGNITIVE DECLINE" (SCD) WHICH OCCURS PRIOR TO THE MCI STAGE. BOTH OF THESE STAGES HAVE SUBSEQUENTLY BECOME "HOUSEHOLD NAMES" IN OUR FIELD. DURING THIS YEAR, WE DISCOVERED A NEW EVEN EARLIER STAGE OF AD, THE FIRST NEW STAGE OF AD IDENTIFIED IN THE PAST SEVERAL DECADES. A REPORT WAS DONE ON THIS STAGE, WHICH WE TERMED, "PSYCHOMETRIC COGNITIVE DECLINE." THIS STAGE PRECEDES THE ADVENT OF SCD. WE RECRUITED 60 HEALTHY PERSONS WITH, "NO COGNITIVE DECLINE." WE FOLLOWED 47 OF THESE PERSONS OVER A MEAN OF 6.7 YEARS. AT FOLLOW-UP, WE CLASSIFIED PERSONS AS DECLINERS IF THEY DEVELOPED SCD OR WORSE AND AS NON-DECLINERS IF THEY REMAINED FREE OF SUBJECTIVE OR OBJECTIVE IMPAIRMENTS. AT FOLLOW-UP, WE FOUND THAT THERE WAS A VERY SIGNIFICANT DIFFERENCE BETWEEN THE TWO GROUPS IN THE DECLINE RATE. AFTER CONTROLLING FOR DEMOGRAPHIC VARIABLES AND FOLLOW-UP TIME, OUR COMBINATORIAL PSYCHOMETRIC TEST SCORE WAS SIGNIFICANTLY LOWER IN THE FUTURE DECLINERS. THIS WAS THE FIRST STUDY TO LINK PSYCHOMETRIC COGNITIVE DECLINE TO EVENTUAL AD. THESE RESULTS WERE PUBLISHED AS A "30TH ANNIVERSARY RESEARCH ARTICLE" IN DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, IN MAY 2020. THESE FINDINGS PROVIDE AN OPPORTUNITY FOR INTERVENTION AT AN EARLIER POINT IN THE EVOLUTION OF EVENTUAL ALZHEIMER'S DISEASE THAN HAS PREVIOUSLY BEEN POSSIBLE. WE ALSO STUDIED THE EFFECT OF OUR COMPREHENSIVE, INDIVIDUALIZED PERSON-CENTERED MANAGEMENT PROGRAM (CI-PCM) ON ANTIDEPRESSANT USAGE IN COMMUNITY-RESIDING, ADVANCED AD PERSONS. WE FOUND THAT THE CI-PCM PERSONS HAD SIGNIFICANT DECREASES IN ANTIDEPRESSANT USAGE AND IN BEHAVIORAL SYMPTOMATOLOGY, AS WELL AS A RESOLUTION OF THEIR DEPRESSIVE SYMPTOMS. THE GROUP WHO RECEIVED USUAL COMMUNITY CARE (UCC) RECEIVED MORE ANTIDEPRESSANT MEDICATION AND PAID 4.2 TIMES MORE FOR ANTIDEPRESSANTS. UCC PERSONS HAD A WORSENING OF BOTH BEHAVIORAL DISTURBANCES AND DEPRESSIVE SYMPTOMS.</Desc>
      </ProgSrvcAccomActyOtherGrp>
      <TotalOtherProgSrvcExpenseAmt>150000</TotalOtherProgSrvcExpenseAmt>
      <TotalOtherProgSrvcGrantAmt>150000</TotalOtherProgSrvcGrantAmt>
      <TotalProgramServiceExpensesAmt>5744317</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="RetDoc1039100001">1</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd referenceDocumentId="RetDoc1234500001">1</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd>0</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd>0</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd>0</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd referenceDocumentId="RetDoc1040000001">0</DonorAdvisedFundInd>
      <ConservationEasementsInd referenceDocumentId="RetDoc1040000001">0</ConservationEasementsInd>
      <CollectionsOfArtInd referenceDocumentId="RetDoc1040000001">0</CollectionsOfArtInd>
      <CreditCounselingInd referenceDocumentId="RetDoc1040000001">0</CreditCounselingInd>
      <DonorRstrOrQuasiEndowmentsInd>0</DonorRstrOrQuasiEndowmentsInd>
      <ReportLandBuildingEquipmentInd referenceDocumentId="RetDoc1040000001">1</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd referenceDocumentId="RetDoc1040000001">0</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd referenceDocumentId="RetDoc1040000001">0</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd referenceDocumentId="RetDoc1040000001">0</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd referenceDocumentId="RetDoc1040000001">0</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd referenceDocumentId="RetDoc1040000001">1</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd referenceDocumentId="RetDoc1040000001">1</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd referenceDocumentId="RetDoc1040000001">0</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>0</SchoolOperatingInd>
      <ForeignOfficeInd>0</ForeignOfficeInd>
      <ForeignActivitiesInd referenceDocumentId="RetDoc1040500001">1</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd referenceDocumentId="RetDoc1040500001">1</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd referenceDocumentId="RetDoc1040500001">0</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd>0</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd>0</FundraisingActivitiesInd>
      <GamingActivitiesInd>0</GamingActivitiesInd>
      <OperateHospitalInd>0</OperateHospitalInd>
      <GrantsToOrganizationsInd referenceDocumentId="RetDoc1041900001">1</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd referenceDocumentId="RetDoc1041900001">0</GrantsToIndividualsInd>
      <ScheduleJRequiredInd referenceDocumentId="RetDoc1042400001">1</ScheduleJRequiredInd>
      <TaxExemptBondsInd>0</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd referenceDocumentId="RetDoc1042800001">0</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd referenceDocumentId="RetDoc1042800001">0</PYExcessBenefitTransInd>
      <LoanOutstandingInd referenceDocumentId="RetDoc1042800001">0</LoanOutstandingInd>
      <GrantToRelatedPersonInd referenceDocumentId="RetDoc1042800001">0</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd referenceDocumentId="RetDoc1042800001">0</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd referenceDocumentId="RetDoc1042800001">0</BusinessRlnWithFamMemInd>
      <BusinessRlnWith35CtrlEntInd>1</BusinessRlnWith35CtrlEntInd>
      <DeductibleNonCashContriInd referenceDocumentId="RetDoc1042900001">1</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd referenceDocumentId="RetDoc1042900001">0</DeductibleArtContributionInd>
      <TerminateOperationsInd>0</TerminateOperationsInd>
      <PartialLiquidationInd>0</PartialLiquidationInd>
      <DisregardedEntityInd>0</DisregardedEntityInd>
      <RelatedEntityInd>0</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>0</RelatedOrganizationCtrlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd>0</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd>0</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>1</ScheduleORequiredInd>
      <IRPDocumentCnt>11</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <EmployeeCnt>4</EmployeeCnt>
      <EmploymentTaxReturnsFiledInd>1</EmploymentTaxReturnsFiledInd>
      <UnrelatedBusIncmOverLimitInd>0</UnrelatedBusIncmOverLimitInd>
      <ForeignFinancialAccountInd>0</ForeignFinancialAccountInd>
      <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>0</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>0</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>0</QuidProQuoContributionsInd>
      <Form8282PropertyDisposedOfInd>0</Form8282PropertyDisposedOfInd>
      <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
      <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
      <IndoorTanningServicesInd>0</IndoorTanningServicesInd>
      <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      <SubjectToExcsTaxNetInvstIncInd>0</SubjectToExcsTaxNetInvstIncInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>12</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>11</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>0</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>0</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>0</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>0</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>0</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>0</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>0</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>1</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>1</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>0</OfficerMailingAddressInd>
      <LocalChaptersInd>0</LocalChaptersInd>
      <Form990ProvidedToGvrnBodyInd>1</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>1</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>1</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>1</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>1</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>1</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>1</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>0</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>0</InvestmentInJointVentureInd>
      <StatesWhereCopyOfReturnIsFldCd>UT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>IL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NJ</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>PA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>RI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>VA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MD</StatesWhereCopyOfReturnIsFldCd>
      <OwnWebsiteInd>X</OwnWebsiteInd>
      <OtherWebsiteInd>X</OtherWebsiteInd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <BusinessName>
          <BusinessNameLine1Txt>LUCRETIA HOLDEN</BusinessNameLine1Txt>
        </BusinessName>
        <PhoneNum>2129151328</PhoneNum>
        <USAddress>
          <AddressLine1Txt>FDR STATION PO BOX 220</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10150</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <Form990PartVIISectionAGrp>
        <PersonNm>BARRY R SLOANE</PersonNm>
        <TitleTxt>CHAIRMAN/TREASURER</TitleTxt>
        <AverageHoursPerWeekRt>6.75</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>HOWARD LUTNICK</PersonNm>
        <TitleTxt>VICE CHAIR</TitleTxt>
        <AverageHoursPerWeekRt>0.25</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MARTIN EDELMAN</PersonNm>
        <TitleTxt>VICE CHAIR</TitleTxt>
        <AverageHoursPerWeekRt>0.25</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>DAVID HW TURNER</PersonNm>
        <TitleTxt>SECRETARY</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>DR MANNY ALVAREZ</PersonNm>
        <TitleTxt>TRUSTEE</TitleTxt>
        <AverageHoursPerWeekRt>0.25</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>DR E RATCLIFFE ANDERSON JR</PersonNm>
        <TitleTxt>TRUSTEE</TitleTxt>
        <AverageHoursPerWeekRt>0.10</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>GERRY BYRNE</PersonNm>
        <TitleTxt>TRUSTEE</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>HADLEY FISHER</PersonNm>
        <TitleTxt>TRUSTEE</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>BETSY GOTBAUM</PersonNm>
        <TitleTxt>TRUSTEE</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JAMES L NEDERLANDER</PersonNm>
        <TitleTxt>TRUSTEE</TitleTxt>
        <AverageHoursPerWeekRt>0.25</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>RICHARD J SALEM</PersonNm>
        <TitleTxt>TRUSTEE</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>DR MOSHE SHIKE</PersonNm>
        <TitleTxt>TRUSTEE</TitleTxt>
        <AverageHoursPerWeekRt>0.25</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LOIS WHITMAN-HESS</PersonNm>
        <TitleTxt>TRUSTEE (THRU MAR 2020))</TitleTxt>
        <AverageHoursPerWeekRt>0.25</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LUCRETIA HOLDEN</PersonNm>
        <TitleTxt>EXECUTIVE DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>40.00</AverageHoursPerWeekRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>213126</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>17383</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>213126</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>0</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>17383</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>1</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>0</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>1</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>0</CompensationFromOtherSrcsInd>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>ELITE ACCOUNTING SERVICES LLC</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>500 MAMARONECK AVE</AddressLine1Txt>
            <CityNm>HARRISON</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10528</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>BOOKKEEPING SERVICES</ServicesDesc>
        <CompensationAmt>123868</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>STAYWELL COMPANY LLC</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>800 TOWNSHIP LINE ROAD</AddressLine1Txt>
            <CityNm>YARDLEY</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>19067</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>MAGAZINE PUBLISHING</ServicesDesc>
        <CompensationAmt>121934</CompensationAmt>
      </ContractorCompensationGrp>
      <CntrctRcvdGreaterThan100KCnt>2</CntrctRcvdGreaterThan100KCnt>
      <FederatedCampaignsAmt>226998</FederatedCampaignsAmt>
      <AllOtherContributionsAmt>7231791</AllOtherContributionsAmt>
      <NoncashContributionsAmt>430439</NoncashContributionsAmt>
      <TotalContributionsAmt>7458789</TotalContributionsAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>383515</TotalRevenueColumnAmt>
        <ExclusionAmt>383515</ExclusionAmt>
      </InvestmentIncomeGrp>
      <GrossAmountSalesAssetsGrp>
        <SecuritiesAmt>5760042</SecuritiesAmt>
      </GrossAmountSalesAssetsGrp>
      <LessCostOthBasisSalesExpnssGrp>
        <SecuritiesAmt>3607040</SecuritiesAmt>
      </LessCostOthBasisSalesExpnssGrp>
      <GainOrLossGrp>
        <SecuritiesAmt>2153002</SecuritiesAmt>
      </GainOrLossGrp>
      <NetGainOrLossInvestmentsGrp>
        <TotalRevenueColumnAmt>2153002</TotalRevenueColumnAmt>
        <ExclusionAmt>2153002</ExclusionAmt>
      </NetGainOrLossInvestmentsGrp>
      <OtherRevenueMiscGrp>
        <Desc>OTHER INCOME</Desc>
        <BusinessCd>900099</BusinessCd>
        <TotalRevenueColumnAmt>385</TotalRevenueColumnAmt>
        <ExclusionAmt>385</ExclusionAmt>
      </OtherRevenueMiscGrp>
      <OtherRevenueTotalAmt>385</OtherRevenueTotalAmt>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>9995691</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>2536902</ExclusionAmt>
      </TotalRevenueGrp>
      <GrantsToDomesticOrgsGrp>
        <TotalAmt>4934013</TotalAmt>
        <ProgramServicesAmt>4934013</ProgramServicesAmt>
      </GrantsToDomesticOrgsGrp>
      <ForeignGrantsGrp>
        <TotalAmt>25000</TotalAmt>
        <ProgramServicesAmt>25000</ProgramServicesAmt>
      </ForeignGrantsGrp>
      <CompCurrentOfcrDirectorsGrp>
        <TotalAmt>230509</TotalAmt>
        <ProgramServicesAmt>172882</ProgramServicesAmt>
        <ManagementAndGeneralAmt>11525</ManagementAndGeneralAmt>
        <FundraisingAmt>46102</FundraisingAmt>
      </CompCurrentOfcrDirectorsGrp>
      <OtherSalariesAndWagesGrp>
        <TotalAmt>289424</TotalAmt>
        <ProgramServicesAmt>147453</ProgramServicesAmt>
        <ManagementAndGeneralAmt>47811</ManagementAndGeneralAmt>
        <FundraisingAmt>94160</FundraisingAmt>
      </OtherSalariesAndWagesGrp>
      <PensionPlanContributionsGrp>
        <TotalAmt>12694</TotalAmt>
        <ProgramServicesAmt>7323</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1687</ManagementAndGeneralAmt>
        <FundraisingAmt>3684</FundraisingAmt>
      </PensionPlanContributionsGrp>
      <OtherEmployeeBenefitsGrp>
        <TotalAmt>20130</TotalAmt>
        <ProgramServicesAmt>10340</ProgramServicesAmt>
        <ManagementAndGeneralAmt>3285</ManagementAndGeneralAmt>
        <FundraisingAmt>6505</FundraisingAmt>
      </OtherEmployeeBenefitsGrp>
      <PayrollTaxesGrp>
        <TotalAmt>34986</TotalAmt>
        <ProgramServicesAmt>21393</ProgramServicesAmt>
        <ManagementAndGeneralAmt>4070</ManagementAndGeneralAmt>
        <FundraisingAmt>9523</FundraisingAmt>
      </PayrollTaxesGrp>
      <FeesForServicesLegalGrp>
        <TotalAmt>12392</TotalAmt>
        <ManagementAndGeneralAmt>12392</ManagementAndGeneralAmt>
      </FeesForServicesLegalGrp>
      <FeesForServicesAccountingGrp>
        <TotalAmt>157906</TotalAmt>
        <ManagementAndGeneralAmt>157906</ManagementAndGeneralAmt>
      </FeesForServicesAccountingGrp>
      <FeesForSrvcInvstMgmntFeesGrp>
        <TotalAmt>73575</TotalAmt>
        <ManagementAndGeneralAmt>73575</ManagementAndGeneralAmt>
      </FeesForSrvcInvstMgmntFeesGrp>
      <FeesForServicesOtherGrp>
        <TotalAmt>106782</TotalAmt>
        <ProgramServicesAmt>18919</ProgramServicesAmt>
        <ManagementAndGeneralAmt>13610</ManagementAndGeneralAmt>
        <FundraisingAmt>74253</FundraisingAmt>
      </FeesForServicesOtherGrp>
      <AdvertisingGrp>
        <TotalAmt>71640</TotalAmt>
        <ProgramServicesAmt>70711</ProgramServicesAmt>
        <ManagementAndGeneralAmt>76</ManagementAndGeneralAmt>
        <FundraisingAmt>853</FundraisingAmt>
      </AdvertisingGrp>
      <OfficeExpensesGrp>
        <TotalAmt>49171</TotalAmt>
        <ProgramServicesAmt>16121</ProgramServicesAmt>
        <ManagementAndGeneralAmt>13732</ManagementAndGeneralAmt>
        <FundraisingAmt>19318</FundraisingAmt>
      </OfficeExpensesGrp>
      <InformationTechnologyGrp>
        <TotalAmt>4014</TotalAmt>
        <ProgramServicesAmt>399</ProgramServicesAmt>
        <ManagementAndGeneralAmt>3223</ManagementAndGeneralAmt>
        <FundraisingAmt>392</FundraisingAmt>
      </InformationTechnologyGrp>
      <RoyaltiesGrp>
        <TotalAmt>156279</TotalAmt>
        <ProgramServicesAmt>30508</ProgramServicesAmt>
        <FundraisingAmt>125771</FundraisingAmt>
      </RoyaltiesGrp>
      <OccupancyGrp>
        <TotalAmt>3586</TotalAmt>
        <ManagementAndGeneralAmt>3586</ManagementAndGeneralAmt>
      </OccupancyGrp>
      <TravelGrp>
        <TotalAmt>1358</TotalAmt>
        <ManagementAndGeneralAmt>1232</ManagementAndGeneralAmt>
        <FundraisingAmt>126</FundraisingAmt>
      </TravelGrp>
      <DepreciationDepletionGrp>
        <TotalAmt>787</TotalAmt>
        <ManagementAndGeneralAmt>787</ManagementAndGeneralAmt>
      </DepreciationDepletionGrp>
      <InsuranceGrp>
        <TotalAmt>1670</TotalAmt>
        <ManagementAndGeneralAmt>1670</ManagementAndGeneralAmt>
      </InsuranceGrp>
      <OtherExpensesGrp>
        <Desc>PRINTING AND PUBLISHING</Desc>
        <TotalAmt>286356</TotalAmt>
        <ProgramServicesAmt>286356</ProgramServicesAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>PROCESSING FEES</Desc>
        <TotalAmt>90138</TotalAmt>
        <ManagementAndGeneralAmt>90138</ManagementAndGeneralAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>DUES &amp; SUBSCRIPTIONS</Desc>
        <TotalAmt>11184</TotalAmt>
        <ProgramServicesAmt>2899</ProgramServicesAmt>
        <ManagementAndGeneralAmt>4702</ManagementAndGeneralAmt>
        <FundraisingAmt>3583</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>MISCELLANEOUS</Desc>
        <TotalAmt>3152</TotalAmt>
        <ManagementAndGeneralAmt>3152</ManagementAndGeneralAmt>
      </OtherExpensesGrp>
      <AllOtherExpensesGrp>
        <TotalAmt>164</TotalAmt>
        <ManagementAndGeneralAmt>164</ManagementAndGeneralAmt>
      </AllOtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>6576910</TotalAmt>
        <ProgramServicesAmt>5744317</ProgramServicesAmt>
        <ManagementAndGeneralAmt>448323</ManagementAndGeneralAmt>
        <FundraisingAmt>384270</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>4148305</BOYAmt>
        <EOYAmt>4063644</EOYAmt>
      </CashNonInterestBearingGrp>
      <SavingsAndTempCashInvstGrp>
        <BOYAmt>9016767</BOYAmt>
        <EOYAmt>8272054</EOYAmt>
      </SavingsAndTempCashInvstGrp>
      <PledgesAndGrantsReceivableGrp>
        <BOYAmt>517434</BOYAmt>
        <EOYAmt>672687</EOYAmt>
      </PledgesAndGrantsReceivableGrp>
      <InventoriesForSaleOrUseGrp>
        <BOYAmt>5107</BOYAmt>
        <EOYAmt>4976</EOYAmt>
      </InventoriesForSaleOrUseGrp>
      <PrepaidExpensesDefrdChargesGrp>
        <BOYAmt>6979</BOYAmt>
        <EOYAmt>15016</EOYAmt>
      </PrepaidExpensesDefrdChargesGrp>
      <LandBldgEquipCostOrOtherBssAmt>12806</LandBldgEquipCostOrOtherBssAmt>
      <LandBldgEquipAccumDeprecAmt>10728</LandBldgEquipAccumDeprecAmt>
      <LandBldgEquipBasisNetGrp>
        <BOYAmt>2865</BOYAmt>
        <EOYAmt>2078</EOYAmt>
      </LandBldgEquipBasisNetGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>17821738</BOYAmt>
        <EOYAmt>21767434</EOYAmt>
      </InvestmentsPubTradedSecGrp>
      <OtherAssetsTotalGrp>
        <BOYAmt>2765</BOYAmt>
        <EOYAmt>1861</EOYAmt>
      </OtherAssetsTotalGrp>
      <TotalAssetsGrp>
        <BOYAmt>31521960</BOYAmt>
        <EOYAmt>34799750</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <BOYAmt>79748</BOYAmt>
        <EOYAmt>240532</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <GrantsPayableGrp>
        <BOYAmt>2810985</BOYAmt>
        <EOYAmt>2204998</EOYAmt>
      </GrantsPayableGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>2890733</BOYAmt>
        <EOYAmt>2445530</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
      <NoDonorRestrictionNetAssetsGrp>
        <BOYAmt>28326376</BOYAmt>
        <EOYAmt>32129483</EOYAmt>
      </NoDonorRestrictionNetAssetsGrp>
      <DonorRestrictionNetAssetsGrp>
        <BOYAmt>304851</BOYAmt>
        <EOYAmt>224737</EOYAmt>
      </DonorRestrictionNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>28631227</BOYAmt>
        <EOYAmt>32354220</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>31521960</BOYAmt>
        <EOYAmt>34799750</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <ReconcilationRevenueExpnssAmt>3418781</ReconcilationRevenueExpnssAmt>
      <NetUnrlzdGainsLossesInvstAmt>304212</NetUnrlzdGainsLossesInvstAmt>
      <OtherChangesInNetAssetsAmt>0</OtherChangesInNetAssetsAmt>
      <InfoInScheduleOPartXIIInd>X</InfoInScheduleOPartXIIInd>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>0</AccountantCompileOrReviewInd>
      <FSAuditedInd>1</FSAuditedInd>
      <FSAuditedBasisGrp>
        <SeparateBasisFinclStmtInd>X</SeparateBasisFinclStmtInd>
      </FSAuditedBasisGrp>
      <AuditCommitteeInd>1</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>0</FederalGrantAuditRequiredInd>
    </IRS990>
    <IRS990ScheduleA documentId="RetDoc1039100001">
      <PublicOrganization170Ind>X</PublicOrganization170Ind>
      <GiftsGrantsContriRcvd170Grp>
        <CurrentTaxYearMinus4YearsAmt>4377975</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>6064311</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>5365421</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>6868429</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>7458789</CurrentTaxYearAmt>
        <TotalAmt>30134925</TotalAmt>
      </GiftsGrantsContriRcvd170Grp>
      <TotalCalendarYear170Grp>
        <CurrentTaxYearMinus4YearsAmt>4377975</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>6064311</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>5365421</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>6868429</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>7458789</CurrentTaxYearAmt>
        <TotalAmt>30134925</TotalAmt>
      </TotalCalendarYear170Grp>
      <SubstantialContributorsTotAmt>1468040</SubstantialContributorsTotAmt>
      <PublicSupportTotal170Amt>28666885</PublicSupportTotal170Amt>
      <GrossInvestmentIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>350202</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>331693</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>324830</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>480283</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>383515</CurrentTaxYearAmt>
        <TotalAmt>1870523</TotalAmt>
      </GrossInvestmentIncome170Grp>
      <OtherIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>1336</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>1790</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>670</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>3000</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>385</CurrentTaxYearAmt>
        <TotalAmt>7181</TotalAmt>
      </OtherIncome170Grp>
      <TotalSupportAmt>32012629</TotalSupportAmt>
      <GrossReceiptsRltdActivitiesAmt>412</GrossReceiptsRltdActivitiesAmt>
      <PublicSupportCY170Pct>0.89550</PublicSupportCY170Pct>
      <PublicSupportPY170Pct>0.87040</PublicSupportPY170Pct>
      <ThirtyThrPctSuprtTestsCY170Ind>X</ThirtyThrPctSuprtTestsCY170Ind>
      <Form990ScheduleAPartVIGrp>
        <FormAndLineReferenceDesc>SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME:</FormAndLineReferenceDesc>
        <ExplanationTxt>MISCELLANEOUS - 2016 AMOUNT: $ 1,336. 2017 AMOUNT: $ 1,790. 2018 AMOUNT: $ 670. 2019 AMOUNT: $ 3,000. 2020 AMOUNT: $ 385.</ExplanationTxt>
      </Form990ScheduleAPartVIGrp>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <ContributorInformationGrp>
        <ContributorNum>RESTRICTED</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorUSAddress>
        <TotalContributionsAmt>RESTRICTED</TotalContributionsAmt>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <IRS990ScheduleD documentId="RetDoc1040000001">
      <EquipmentGrp>
        <OtherCostOrOtherBasisAmt>12806</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>10728</DepreciationAmt>
        <BookValueAmt>2078</BookValueAmt>
      </EquipmentGrp>
      <TotalBookValueLandBuildingsAmt>2078</TotalBookValueLandBuildingsAmt>
      <FootnoteTextInd>X</FootnoteTextInd>
      <TotalRevEtcAuditedFinclStmtAmt>10537766</TotalRevEtcAuditedFinclStmtAmt>
      <NetUnrealizedGainsInvstAmt>304212</NetUnrealizedGainsInvstAmt>
      <DonatedServicesAndUseFcltsAmt>311438</DonatedServicesAndUseFcltsAmt>
      <RevenueNotReportedAmt>615650</RevenueNotReportedAmt>
      <RevenueSubtotalAmt>9922116</RevenueSubtotalAmt>
      <InvestmentExpensesNotIncldAmt>73575</InvestmentExpensesNotIncldAmt>
      <RevenueNotReportedFinclStmtAmt>73575</RevenueNotReportedFinclStmtAmt>
      <TotalRevenuePerForm990Amt>9995691</TotalRevenuePerForm990Amt>
      <TotExpnsEtcAuditedFinclStmtAmt>6814773</TotExpnsEtcAuditedFinclStmtAmt>
      <DonatedServicesUseFcltsAmt>311438</DonatedServicesUseFcltsAmt>
      <ExpensesNotReportedAmt>311438</ExpensesNotReportedAmt>
      <ExpensesSubtotalAmt>6503335</ExpensesSubtotalAmt>
      <InvestmentExpensesNotIncld2Amt>73575</InvestmentExpensesNotIncld2Amt>
      <ExpensesNotRptFinclStmtAmt>73575</ExpensesNotRptFinclStmtAmt>
      <TotalExpensesPerForm990Amt>6576910</TotalExpensesPerForm990Amt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART X, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES - THE FOUNDATION RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE FOUNDATION HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. THE FOUNDATION IS NO LONGER SUBJECT TO EXAMINATIONS BY THE APPLICABLE TAXING JURISDICTIONS FOR TAX YEARS PRIOR TO 2017.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="RetDoc1040500001">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EUROPE</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>GRANTMAKING</TypeOfActivitiesConductedTxt>
        <RegionTotalExpendituresAmt>25000</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <SubtotalOfficesCnt>0</SubtotalOfficesCnt>
      <SubtotalEmployeesCnt>0</SubtotalEmployeesCnt>
      <ContinuationTotalOfficeCnt>0</ContinuationTotalOfficeCnt>
      <ContinuationTotalEmployeeCnt>0</ContinuationTotalEmployeeCnt>
      <TotalOfficeCnt>0</TotalOfficeCnt>
      <TotalEmployeeCnt>0</TotalEmployeeCnt>
      <SubtotalSpentAmt>25000</SubtotalSpentAmt>
      <ContinuationSpentAmt>0</ContinuationSpentAmt>
      <TotalSpentAmt>25000</TotalSpentAmt>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>EUROPE</RegionTxt>
        <PurposeOfGrantTxt>ALZHEIMER'S RESEARCH</PurposeOfGrantTxt>
        <CashGrantAmt>25000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>WIRE TRANSFER</MannerOfCashDisbursementTxt>
      </GrantsToOrgOutsideUSGrp>
      <Total501c3OrgCnt>1</Total501c3OrgCnt>
      <TotalOtherOrgCnt>0</TotalOtherOrgCnt>
      <TransferToForeignCorpInd>0</TransferToForeignCorpInd>
      <InterestInForeignTrustInd>0</InterestInForeignTrustInd>
      <ForeignCorpOwnershipInd>0</ForeignCorpOwnershipInd>
      <PassiveForeignInvestmestCoInd>0</PassiveForeignInvestmestCoInd>
      <ForeignPartnershipInd>0</ForeignPartnershipInd>
      <BoycottCountriesInd>0</BoycottCountriesInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>A SINGLE GRANT WAS GIVEN TO A RESEARCH INSTITUTE IN EUROPE FOR PROGRAM-RELATED RESEARCH. THE GRANTEE ORGANIZATION PROVIDED THE ORGANIZATION WITH MONTHLY REPORTS ON THE PROGRESS OF THEIR INVESTIGATIONS, AS WELL AS A FINAL REPORT AT THE END OF THE AGREEMENT.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 3:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION USES THE ACCRUAL METHOD OF ACCOUNTING TO ACCOUNT FOR ITS FOREIGN EXPENDITURES.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART III ACCOUNTING METHOD:</FormAndLineReferenceDesc>
      </SupplementalInformationDetail>
    </IRS990ScheduleF>
    <IRS990ScheduleI documentId="RetDoc1041900001">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>THE ROCKEFELLER UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1230 YORK AVENUE</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10021</ZIPCd>
        </USAddress>
        <RecipientEIN>131624158</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>4750000</CashGrantAmt>
        <PurposeOfGrantTxt>NEUROLOGICAL RESEARCH INTO THE CAUSES OF ALZHEIMER'S DISEASE, POTENTIAL NEW PHARMACOLOGICAL TREATMENT OPTIONS, PROFESSORSHIP TO CONDUCT RESEARCH ACTIVITIES, AND COVID-19 RESEARCH."</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>NEW YORK UNIVERSITY SCHOOL OF MEDICINE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>550 FIRST AVENUE</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10016</ZIPCd>
        </USAddress>
        <RecipientEIN>135562308</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>125000</CashGrantAmt>
        <PurposeOfGrantTxt>CLINICAL RESEARCH INTO THE EFFICACY OF MEMANTINE, AND COMPREHENSIVE INDIVIDUALIZED PATIENT-CENTERED MANAGEMENT OF ALZHEIMER'S DISEASE.</PurposeOfGrantTxt>
      </RecipientTable>
      <Total501c3OrgCnt>2</Total501c3OrgCnt>
      <TotalOtherOrgCnt>0</TotalOtherOrgCnt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION MONITORS THE USE OF GRANT FUNDS IN THE US BY RECEIVING PERIODIC PROGRESS REPORTS ON THE RESEARCH CONDUCTED AND ANY FINDINGS PUBLISHED AS A RESULT OF THIS FUNDING. THE FISHER CENTER FOR ALZHEIMER'S DISEASE RESEARCH AT THE ROCKEFELLER UNIVERSITY SUBMITS A REPORT AT EACH GENERAL BOARD MEETING WHICH IS INCORPORATED INTO THE MINUTES OF THE MEETING. THE FISHER EDUCATIONAL AND RESOURCES PROGRAM AT NYU SCHOOL OF MEDICINE REPORTS AT THE END OF THE FUNDING PERIOD IN THEIR REQUEST FOR FURTHER FUNDING ON THE PROGRESS TO DATE OF THE RESEARCH ACTIVITIES SUPPORTED BY THE FOUNDATION. THE FOUNDATION FUNDING DECISIONS ARE MADE UNDER THE SOLE AND ABSOLUTE DISCRETION OF THE BOARD PURSUANT TO A MAJORITY VOTE. A SCIENCE ADVISORY BOARD COMPRISED OF MEDICAL AND SCIENTIFIC EXPERTS IN THE FIELD OF ALZHEIMER'S DISEASE AND RELATED DISEASES ADVISES AND ASSISTS THE FOUNDATION IN CONNECTION WITH FUNDING GRANT REQUESTS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, SCHEDULE I, PART II, COLUMN (H):</FormAndLineReferenceDesc>
        <ExplanationTxt>GRANTS TO THE ROCKEFELLER UNIVERSITY: THE GRANTEE PROVIDES PERIODIC PROGRESS REPORTS ON THE RESEARCH CONDUCTED AND ANY FINDINGS PUBLISHED, AND ALSO SUBMITS A REPORT FOR EACH GENERAL BOARD MEETING WHICH IS INCORPORATED INTO THE MINUTES OF THE MEETING. GRANT TO NYU MEDICAL CENTER: THE GRANTEE PROVIDES A REPORT AT THE END OF THE FUNDING PERIOD ON THE PROGRESS TO DATE OF THE RESEARCH ACTIVITIES.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleI>
    <IRS990ScheduleJ documentId="RetDoc1042400001">
      <CompensationCommitteeInd>X</CompensationCommitteeInd>
      <Form990OfOtherOrganizationsInd>X</Form990OfOtherOrganizationsInd>
      <CompensationSurveyInd>X</CompensationSurveyInd>
      <BoardOrCommitteeApprovalInd>X</BoardOrCommitteeApprovalInd>
      <SeverancePaymentInd>0</SeverancePaymentInd>
      <SupplementalNonqualRtrPlanInd>0</SupplementalNonqualRtrPlanInd>
      <EquityBasedCompArrngmInd>0</EquityBasedCompArrngmInd>
      <CompBasedOnRevenueOfFlngOrgInd>0</CompBasedOnRevenueOfFlngOrgInd>
      <CompBsdOnRevRelatedOrgsInd>0</CompBsdOnRevRelatedOrgsInd>
      <CompBsdNetEarnsFlngOrgInd>0</CompBsdNetEarnsFlngOrgInd>
      <CompBsdNetEarnsRltdOrgsInd>0</CompBsdNetEarnsRltdOrgsInd>
      <AnyNonFixedPaymentsInd>1</AnyNonFixedPaymentsInd>
      <InitialContractExceptionInd>0</InitialContractExceptionInd>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>LUCRETIA HOLDEN</PersonNm>
        <TitleTxt>EXECUTIVE DIRECTOR</TitleTxt>
        <BaseCompensationFilingOrgAmt>163126</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>50000</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>3171</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>14212</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>230509</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 7</FormAndLineReferenceDesc>
        <ExplanationTxt>THE EXECUTIVE DIRECTOR, LUCRETIA HOLDEN, WAS AWARDED A BONUS OF $50,000 BY A UNANIMOUS VOTE OF THE COMPENSATION COMMITTEE OF THE BOARD, WHICH IS REPORTED ON SCHEDULE J, PART II, COLUMN B(III).</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleJ>
    <IRS990ScheduleL documentId="RetDoc1042800001">
      <BusTrInvolveInterestedPrsnGrp>
        <NameOfInterested>
          <BusinessName>
            <BusinessNameLine1Txt>CENTURY BANK</BusinessNameLine1Txt>
          </BusinessName>
        </NameOfInterested>
        <RelationshipDescriptionTxt>SEE PART V</RelationshipDescriptionTxt>
        <TransactionAmt>6650029</TransactionAmt>
        <TransactionDesc>SEE PART V</TransactionDesc>
        <SharingOfRevenuesInd>0</SharingOfRevenuesInd>
      </BusTrInvolveInterestedPrsnGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, SCHEDULE L, PART IV</FormAndLineReferenceDesc>
        <ExplanationTxt>RESULTING FROM HIGHLY COMPETITIVE RATES OFFERED BY CENTURY BANK, THE FOUNDATION HOLDS $6,650,029 IN CERTIFICATES OF DEPOSIT AND A MONEY MARKET ACCOUNT WITH CENTURY BANK, WHERE MR. BARRY SLOANE (THE FOUNDATION'S CHAIRMAN/TREASURER) SERVES AS PRESIDENT AND CEO. MR. BARRY SLOANE AND HIS FAMILY MEMBERS OWN MORE THAN 35% OF THE TOTAL COMBINED VOTING POWER OF CENTURY BANK. THE ENTIRE BOARD WAS MADE AWARE OF THE CONFLICT WITH MR. SLOANE BEFORE THE INVESTMENTS WERE MADE, AS WELL AS A CONTINUING DISCLOSURE AT ALL SUBSEQUENT BOARD MEETINGS. THE BOARD UNANIMOUSLY VOTED TO APPROVE THE INVESTMENTS. MR. SLOANE RECUSED HIMSELF FROM THE VOTE.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleL>
    <IRS990ScheduleM documentId="RetDoc1042900001">
      <SecuritiesPubliclyTradedGrp>
        <NonCashCheckboxInd>X</NonCashCheckboxInd>
        <ContributionCnt>46</ContributionCnt>
        <NoncashContributionsRptF990Amt>430439</NoncashContributionsRptF990Amt>
        <MethodOfDeterminingRevenuesTxt>AVG SELLING PRICE</MethodOfDeterminingRevenuesTxt>
      </SecuritiesPubliclyTradedGrp>
      <Form8283ReceivedCnt>0</Form8283ReceivedCnt>
      <AnyPropertyThatMustBeHeldInd>0</AnyPropertyThatMustBeHeldInd>
      <ReviewProcessUnusualNCGiftsInd>1</ReviewProcessUnusualNCGiftsInd>
      <ThirdPartiesUsedInd>0</ThirdPartiesUsedInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, COLUMN (B):</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTIONS ON PART I, LINE 9, COLUMN (B).</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleM>
    <IRS990ScheduleO documentId="RetDoc1044400001">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 11B</FormAndLineReferenceDesc>
        <ExplanationTxt>THE 990 IS INITIALLY REVIEWED BY MEMBERS OF THE AUDIT COMMITTEE THAT CONSISTS OF 3 INDEPENDENT TRUSTEES. A COPY IS THEN FORWARDED ELECTRONICALLY TO ALL BOARD MEMBERS AND RELEVANT MANAGEMENT PERSONNEL FOR THEIR REVIEW AND COMMENT. ANY REQUIRED REVISIONS ARE MADE AND THE REVISED 990 IS RESUBMITTED TO ALL BOARD MEMBERS FOR FINAL REVIEW BEFORE FILING.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 12C</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION HAS A CONFLICT OF INTEREST POLICY WHICH IS ANNUALLY MONITORED REQUIRING ALL TRUSTEES TO DISCLOSE ANY POSSIBLE CONFLICT OF INTEREST VIA EMAIL RESPONSE TO THE EXECUTIVE DIRECTOR. THE FOUNDATION REQUIRES THAT ALL TRUSTEES, OFFICERS, KEY EMPLOYEES AND STAFF PERSONNEL PROMPTLY AND FULLY DISCLOSE ALL MATERIAL FACTS OF ANY ACTUAL OR POTENTIAL CONFLICT OF INTEREST THAT MAY EXIST AT THE TIME THE TRUSTEE IS APPOINTED OR STAFF PERSONNEL IS HIRED, OR AS THEY MAY ARISE WHILE THE TRUSTEE IS SERVING ON THE BOARD OR THE STAFF PERSONNEL IS EMPLOYED BY THE FOUNDATION. SUCH DISCLOSURES INVOLVING A TRANSACTION, ARRANGEMENT OR DECISION BEING CONSIDERED BY THE BOARD ARE MADE KNOWN TO ALL TRUSTEES. THE BOARD THEN DETERMINES WHETHER A CONFLICT OF INTEREST EXISTS WITH THE INTERESTED PARTY ABSTAINING FROM THE DECISION. IF IT IS DETERMINED THAT NO CONFLICT EXISTS, THEN THE BOARD VOTES ON THE TRANSACTION BUT WITH THE INTERESTED PARTY RECUSING HIMSELF FROM THE DISCUSSION AND VOTE ON SAID MATTER.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 15A</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION HAS A COMPENSATION COMMITTEE CONSISTING OF 3 INDEPENDENT TRUSTEES TO DETERMINE THE COMPENSATION OF TOP MANAGEMENT AND KEY EMPLOYEES AT LEAST ONCE A YEAR. THE COMMITTEE IS MANDATED BY ITS CHARTER TO REVIEW EXECUTIVE AND OTHER KEY EMPLOYEE PERFORMANCE CONSISTENT WITH THE GOALS AND OBJECTIVES OF THE FOUNDATION AS DETERMINED BY THE BOARD OF TRUSTEES, AND TO DETERMINE AN APPROPRIATE LEVEL OF COMPENSATION IN LIGHT OF THIS PERFORMANCE REVIEW AND USING OTHER SUBSTANTIATING DATA SURVEYS ON CURRENT COMPENSATION RATES FOR SIMILAR POSITIONS IN OTHER COMPARABLE NONPROFITS IN THE NEW YORK CITY AREA. THE COMMITTEE'S DECISION IS DOCUMENTED IN A CONTEMPORANEOUSLY WRITTEN FORMAT (COMPENSATION COMMITTEE MINUTES) INDICATING THE DATE OF THE MEETING, THE MEMBERS PRESENT, AND THE COMPARABLE DATA USED TO MAKE THE DECISION. THE COMPENSATION REVIEW PROCESS FOR THE EXECUTIVE DIRECTOR WAS LAST UNDERTAKEN IN DECEMBER 2020.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION C, LINE 19</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION MAKES ITS FORM 990 AND AUDITED FINANCIAL STATEMENTS AVAILABLE FOR PUBLIC INSPECTION BY POSTING IT ON THEIR WEBSITE. THE FORM 990 IS AVAILABLE ON OTHER WEBSITES, SUCH AS WWW.GUIDESTAR.ORG. IN ADDITION, GOVERNING DOCUMENTS, THE FORM 990, AUDITED FINANCIAL STATEMENTS, CONFLICT OF INTEREST POLICY AND OTHER POLICIES ARE AVAILABLE UPON WRITTEN REQUEST AT FDR STATION, P.O. BOX 220, NEW YORK NY 10150 OR BY CALLING THE ORGANIZATION DIRECTLY AT (800) 259-4636 OR (212) 915-1328.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART XII, LINE 2C:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION HAS AN AUDIT COMMITTEE THAT IS RESPONSIBLE FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND THE SELECTION OF AN INDEPENDENT ACCOUNTANT. THE PROCESS HAS NOT CHANGED FROM THE PREVIOUS YEAR.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
  </ReturnData>
</Return>
